Neumora Therapeutics (NASDAQ:NMRA) Given Outperform Rating at William Blair

William Blair restated their outperform rating on shares of Neumora Therapeutics (NASDAQ:NMRA) in a research report sent to investors on Wednesday morning,RTT News reports.

Other equities analysts have also issued research reports about the stock. JPMorgan Chase & Co. lowered shares of Neumora Therapeutics from an “overweight” rating to a “neutral” rating and reduced their price target for the company from $18.00 to $15.00 in a research report on Tuesday, November 5th. HC Wainwright reiterated a “buy” rating and set a $30.00 target price on shares of Neumora Therapeutics in a research report on Friday, January 3rd. Royal Bank of Canada lowered shares of Neumora Therapeutics from an “outperform” rating to a “sector perform” rating and cut their target price for the stock from $29.00 to $4.00 in a research report on Thursday, January 2nd. Bank of America cut their target price on shares of Neumora Therapeutics from $22.00 to $7.00 and set a “buy” rating for the company in a research report on Monday, January 6th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $23.00 price target on shares of Neumora Therapeutics in a report on Thursday, January 2nd. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $16.50.

Neumora Therapeutics Trading Down 3.5 %

NASDAQ NMRA opened at $2.20 on Wednesday. Neumora Therapeutics has a 1 year low of $1.83 and a 1 year high of $21.00. The company has a fifty day moving average price of $9.16 and a 200-day moving average price of $11.17.

Neumora Therapeutics (NASDAQ:NMRA) last posted its earnings results on Tuesday, November 12th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.06). During the same period in the previous year, the company posted ($1.14) EPS. Equities research analysts forecast that Neumora Therapeutics will post -1.61 EPS for the current year.

Insider Activity at Neumora Therapeutics

In related news, Director Matthew K. Fust sold 14,049 shares of Neumora Therapeutics stock in a transaction on Friday, October 18th. The shares were sold at an average price of $17.03, for a total value of $239,254.47. Following the sale, the director now owns 20,100 shares in the company, valued at $342,303. The trade was a 41.14 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 26.40% of the stock is currently owned by company insiders.

Institutional Trading of Neumora Therapeutics

Several large investors have recently added to or reduced their stakes in the stock. Amalgamated Bank lifted its position in Neumora Therapeutics by 472.8% during the second quarter. Amalgamated Bank now owns 2,910 shares of the company’s stock valued at $29,000 after buying an additional 2,402 shares during the period. Quarry LP purchased a new position in Neumora Therapeutics during the second quarter valued at $98,000. Intech Investment Management LLC purchased a new position in Neumora Therapeutics during the third quarter valued at $175,000. Ballentine Partners LLC purchased a new position in Neumora Therapeutics during the third quarter valued at $178,000. Finally, SkyOak Wealth LLC purchased a new position in Neumora Therapeutics during the second quarter valued at $147,000. Institutional investors own 47.65% of the company’s stock.

Neumora Therapeutics Company Profile

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.